| scholarly article | Q13442814 |
| P2093 | author name string | Elvira C van Dalen | |
| Frank Peinemann | |||
| Frank Berthold | |||
| Heike Enk | |||
| P2860 | cites work | Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer | Q73863065 |
| A case of growth failure caused by 13-CIS-retinoic acid administration after bone marrow transplantation for neuroblasoma | Q74258091 | ||
| Phase II Trial of the Anti-GD2Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma | Q77174625 | ||
| Fenretinide: the death of a tumor cell | Q77960728 | ||
| A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study | Q80089819 | ||
| Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97 | Q80894676 | ||
| Clinical trials referral resource | Q81468155 | ||
| 13‐cis‐retinoic acid‐associated bone marrow edema in neuroblastoma | Q83485312 | ||
| Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma | Q83857253 | ||
| When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care? | Q85999573 | ||
| Skeletal impact of retinoid therapy in childhood cancer survivors | Q88148473 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation | Q24186451 | ||
| High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma | Q24186636 | ||
| Retinoic acid post consolidation therapy for high-risk neuroblastoma | Q24201495 | ||
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma | Q24602657 | ||
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study | Q24658339 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant | Q71773260 | ||
| Generalized metaphyseal modification with cone-shaped epiphyses following long-term administration of 13-cis-retinoic acid | Q73478389 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. | Q30532640 | ||
| Neuroblastoma in adults: Incidence and survival analysis based on SEER data | Q31037361 | ||
| Possible association of retinoic acid with bone marrow transplant nephropathy | Q33330959 | ||
| Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report | Q33390536 | ||
| Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. | Q33391308 | ||
| Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation | Q33489400 | ||
| Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. | Q33791667 | ||
| Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group | Q33876841 | ||
| Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. | Q34056803 | ||
| Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption | Q34315331 | ||
| Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. | Q34351596 | ||
| Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study | Q34444894 | ||
| A proposed staging for children with neuroblastoma.Children's cancer study group A | Q34701554 | ||
| Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas | Q34711600 | ||
| High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial | Q34756587 | ||
| Retinoid therapy of high-risk neuroblastoma. | Q35184993 | ||
| Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group | Q35511099 | ||
| Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study | Q35565630 | ||
| A comparison of current neuroblastoma chemotherapeutics | Q35609684 | ||
| Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study | Q35798960 | ||
| Trial of an aromatic retinoid in patients with solid tumours | Q36045985 | ||
| Promising therapeutic targets in neuroblastoma | Q36055313 | ||
| Favorable histology, MYCN-amplified 4S neonatal neuroblastoma | Q36333671 | ||
| Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. | Q36609788 | ||
| A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy | Q36622068 | ||
| Stage 4S neuroblastoma, a disseminated tumor with excellent outcome. | Q36654154 | ||
| Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin | Q36782374 | ||
| Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial | Q37658501 | ||
| Practical implications for the administration of 13-cis retinoic acid in pediatric oncology | Q37872230 | ||
| Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project | Q37876586 | ||
| Assessment of reporting quality of conference abstracts in sports injury prevention according to CONSORT and STROBE criteria and their subsequent publication rate as full papers | Q38001788 | ||
| 131I‐MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma | Q38048241 | ||
| Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review | Q38787392 | ||
| New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome | Q39639490 | ||
| Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide | Q40038033 | ||
| Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent children's cancer group results | Q40423562 | ||
| Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure. | Q40482654 | ||
| Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy | Q40509655 | ||
| Autologous stem cell transplantation in solid tumours of childhood | Q41056708 | ||
| Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. | Q41663772 | ||
| Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group | Q41842569 | ||
| The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report | Q41883212 | ||
| Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: A Pediatric Oncology Group study: A Report from the Children's Oncology Group | Q41946476 | ||
| 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. | Q41950761 | ||
| Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid. | Q42286167 | ||
| Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. | Q42485983 | ||
| Therapeutic experience of childhood stage III neuroblastoma | Q42848864 | ||
| Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients | Q43039675 | ||
| Is there a role for retinoids to treat minimal residual disease in neuroblastoma? | Q43202498 | ||
| Complete objective response of neuroblastoma to biological treatment | Q43221859 | ||
| Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults | Q43770759 | ||
| Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines | Q44036425 | ||
| Sweet syndrome associated with 13-cis-retinoic acid (isotretinoin) therapy | Q44236083 | ||
| Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study | Q44403159 | ||
| Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. | Q44471521 | ||
| Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy | Q44504223 | ||
| Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience | Q44640859 | ||
| Pneumocystis carinii pneumonia: a late presentation following treatment for stage IV neuroblastoma | Q44664542 | ||
| Fenretinide activates a distinct apoptotic pathway | Q45038671 | ||
| Retinoic acid may increase the risk of bone marrow transplant nephropathy. | Q45272407 | ||
| Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. | Q45924230 | ||
| Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma. | Q45984797 | ||
| Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. | Q46032981 | ||
| Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). | Q46068154 | ||
| Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma | Q46142720 | ||
| Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. | Q46280595 | ||
| Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma | Q46328341 | ||
| Total rod ERG suppression with high dose compassionate Fenretinide usage | Q46559636 | ||
| Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. | Q46759209 | ||
| Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme | Q46878582 | ||
| Chronic metastatic neuroblastoma | Q46968058 | ||
| Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma | Q48183608 | ||
| Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7). | Q48372855 | ||
| Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. | Q48832189 | ||
| Predicting, Monitoring, and Managing Hypercalcemia Secondary to 13-Cis-Retinoic Acid Therapy in Children With High-risk Neuroblastoma | Q50901973 | ||
| Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study | Q50949517 | ||
| Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. | Q50980368 | ||
| Hypercalcemia induced by 13 cis-retinoic acid in patients with neuroblastoma | Q53490816 | ||
| Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases | Q53576874 | ||
| Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study | Q57262599 | ||
| Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study | Q57734295 | ||
| Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen | Q62662223 | ||
| [1st clinical experience with subtoxic vitamin A doses during radiation and cytostatic tumor therapy] | Q68448966 | ||
| ASCO/AACR: shared emphases and separate meetings | Q70724937 | ||
| Hypervitaminosis A as a complication of treatment for neuroblastoma | Q70995512 | ||
| P921 | main subject | neuroblastoma | Q938205 |
| tretinoin | Q29417 | ||
| P304 | page(s) | CD010685 | |
| P577 | publication date | 2017-08-25 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation | |
| P478 | volume | 8 |
| Q64056920 | Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells |
| Q56341805 | Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro |
| Q58544569 | Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy |
Search more.